oxazolidin-2-one has been researched along with Dyslipidemias in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (13.79) | 29.6817 |
| 2010's | 25 (86.21) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avorn, J; Franklin, JM; Hey, SP; Kesselheim, AS | 1 |
| Chen, D; Gao, P; Wang, Y; Zhang, Q; Zhou, J | 1 |
| Ballantyne, CM; Catapano, AL; Norata, GD | 1 |
| Akinsanya, KO; Castro-Perez, J; Chen, Y; Daniels, E; Johns, DG; Previs, SF; Roddy, TP; Wang, SP; Zhou, H | 1 |
| Kikuchi, M; McCrary Sisk, C; Nakagomi, M; Numaguchi, H; Shirakawa, M; Surks, HK; Tamura, S; Teramoto, T | 1 |
| Cai, J; Chen, C; Hu, Z; Li, C; Li, Y; Liu, L; Luo, H; Pei, F; Zeng, C; Zhang, W; Zhou, F; Zhou, L | 1 |
| Dong, B; Fung, C; Kan, K; Liu, J; Singh, AB | 1 |
| Briand, F; Burr, N; Johns, DG; Muzotte, E; Sulpice, T; Thieblemont, Q; Urbain, I | 1 |
| Berbée, JF; Havekes, LM; Jukema, JW; Kühnast, S; Pieterman, EJ; Princen, HM; Rensen, PC; van der Hoorn, JW; van der Tuin, SJ; Verschuren, L; Wang, Y; Willems van Dijk, K | 1 |
| Burnett, JR; Hooper, AJ; Page, MM | 1 |
| Asztalos, B; Baer, AL; Coromilas, E; deGoma, EM; Donovan, DS; Dunbar, RL; Ginsberg, HN; Gutstein, DE; Holleran, S; Johnson-Levonas, AO; Jumes, P; Karmally, W; Lassman, ME; Liu, Y; Millar, JS; Ngai, C; Rader, DJ; Rafeek, H; Ramakrishnan, R; Reyes-Soffer, G; Thomas, T; Wagner, JA | 1 |
| Borghi, C; Cicero, AF | 1 |
| Ashraf, TB; Ballantyne, CM; Cressman, MD; Gill, GG; Hunter, JA; Johnson-Levonas, AO; Kher, U; Mitchel, YB; Shah, S | 1 |
| Crucet, M; Doycheva, P; Giral, H; Jukema, JW; Kratzer, A; Kühnast, S; Landmesser, U; Lüscher, TF; Mocharla, P; Osto, E; Princen, HM; Simic, B; Speer, T; Staels, B; Stivala, S; Tailleux, A; van der Hoorn, JW | 1 |
| Bloomfield, D; Carlson, GL; Littlejohn, TW; McKenney, JM; Mitchel, Y; Pasternak, RC; Sapre, A; Sisk, CM; Tribble, D | 1 |
| Al-Huniti, N; Archer, L; Bergman, AJ; Chavez-Eng, C; Chen, J; Cote, J; Dykstra, K; Garg, A; Gottesdiener, K; Hilliard, D; Jin, B; Krishna, R; Laethem, T; Lasseter, KC; Lutz, R; Panebianco, D; Snyder, K; Van Bortel, L; Van Dyck, K; Van Hoydonck, P; Wagner, JA | 1 |
| Fisher, T; Hubbard, B; Kling, J; Li, H; Pagler, T; Sparrow, CP; Taggart, AK; Tall, AR; Yvan-Charvet, L | 1 |
| Miyares, MA | 1 |
| Athyros, VG; Katsiki, N; Mikhailidis, DP | 1 |
| Devaraj, S; Jialal, I | 1 |
| Briand, F; Castro-Perez, J; Chen, Y; Gagen, K; Hankemeier, T; Hubbard, BK; Johns, DG; McLaren, DG; Roddy, TP; Shah, V; Sulpice, T; Vreeken, RJ; Wang, SP | 1 |
| Alivanis, P; Aperis, G; Paliouras, C; Papakonstantinou, N; Tsampikaki, E | 1 |
| Shinkai, H | 1 |
| Davis, K; Miyares, MA | 1 |
| Goldberg, AS; Hegele, RA | 1 |
| Anderson, MS; Bergman, AJ; Bieberdorf, F; Bloomfield, DM; Chavez-Eng, C; Chodakewitz, J; Cote, J; Doherty, J; Fallon, M; Gottesdiener, KM; Gutierrez, M; Jin, B; Krishna, R; Lutz, R; Rosko, K; Wagner, JA | 1 |
| Duriez, P | 1 |
11 review(s) available for oxazolidin-2-one and Dyslipidemias
| Article | Year |
|---|---|
Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein Inhibitors.
Topics: Amides; Anticholesteremic Agents; Benzodiazepines; Biomarkers, Pharmacological; Cholesterol Ester Transfer Proteins; Drug Approval; Drug Discovery; Dyslipidemias; Endpoint Determination; Esters; Humans; Lipids; Oxazolidinones; Predictive Value of Tests; Quinolines; Reproducibility of Results; Sulfhydryl Compounds; Time Factors; Treatment Outcome | 2017 |
The effect and safety of anacetrapib in the treatment of dyslipidemia: a systematic review and meta-analysis.
Topics: Anticholesteremic Agents; Dyslipidemias; Humans; Oxazolidinones | 2018 |
New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs.
Topics: Azetidines; Benzimidazoles; Benzodiazepines; Carrier Proteins; Cholesterol, LDL; Dicarboxylic Acids; Dyslipidemias; Ezetimibe; Fatty Acids; Humans; Hypolipidemic Agents; Lipoprotein(a); Oligonucleotides; Oxazolidinones; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases | 2013 |
Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis.
Topics: Adult; Amides; Anticholesteremic Agents; Benzodiazepines; Blood Pressure; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Esters; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Oxazolidinones; Quinolines; Randomized Controlled Trials as Topic; Sulfhydryl Compounds; Treatment Outcome; Triglycerides | 2013 |
Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?
Topics: Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Molecular Targeted Therapy; Oxazolidinones; Risk Factors | 2016 |
Pharmacokinetic drug evaluation of anacetrapib for the treatment of dyslipidemia.
Topics: Animals; Anticholesteremic Agents; Area Under Curve; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Dyslipidemias; Half-Life; Humans; Liver Diseases; Oxazolidinones | 2017 |
Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors.
Topics: Amides; Animals; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Drug Interactions; Dyslipidemias; Esters; Humans; Lipid Regulating Agents; Oxazolidinones; Sulfhydryl Compounds | 2011 |
Anacetrapib: a new weapon against dyslipidemia.
Topics: Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Metabolic Syndrome; Oxazolidinones | 2011 |
Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
Topics: Amides; Animals; Biomarkers; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Esters; Humans; Hypolipidemic Agents; Oxazolidinones; Quinolines; Sulfhydryl Compounds; Treatment Outcome | 2012 |
Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.
Topics: Biomarkers; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Oxazolidinones; Patient Selection; Risk Assessment; Risk Factors; Treatment Outcome | 2012 |
Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib.
Topics: Amides; Anticholesteremic Agents; Benzodiazepines; Cholesterol Ester Transfer Proteins; Dyslipidemias; Esters; Humans; Lipoproteins, HDL; Oxazolidinones; Sulfhydryl Compounds | 2012 |
6 trial(s) available for oxazolidin-2-one and Dyslipidemias
| Article | Year |
|---|---|
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol Ester Transfer Proteins; Dose-Response Relationship, Drug; Double-Blind Method; Dyslipidemias; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Japan; Male; Middle Aged; Oxazolidinones; Patient Safety; Pyrroles; Time Factors; Treatment Outcome; Young Adult | 2013 |
Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoprotein A-II; Biomarkers; Cholesterol Ester Transfer Proteins; Double-Blind Method; Dyslipidemias; Female; Humans; Lipoproteins, HDL; Male; Middle Aged; Oxazolidinones; Time Factors; Treatment Outcome | 2016 |
Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
Topics: Aged; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Niacin; Oxazolidinones; Treatment Outcome | 2017 |
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol Ester Transfer Proteins; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Middle Aged; Oxazolidinones; Pyrroles; Treatment Outcome | 2009 |
Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Cholesterol Ester Transfer Proteins; Cross-Over Studies; Double-Blind Method; Dyslipidemias; Fasting; Female; Humans; Male; Middle Aged; Obesity; Oxazolidinones; Sex Factors; Treatment Outcome; Young Adult | 2009 |
Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.
Topics: Adolescent; Adult; Aged; Blood Pressure; Cholesterol Ester Transfer Proteins; Dose-Response Relationship, Drug; Double-Blind Method; Dyslipidemias; Electrocardiography; Female; Humans; Male; Middle Aged; Oxazolidinones | 2007 |
12 other study(ies) available for oxazolidin-2-one and Dyslipidemias
| Article | Year |
|---|---|
In vivo effects of anacetrapib on preβ HDL: improvement in HDL remodeling without effects on cholesterol absorption.
Topics: Amides; Animals; Anticholesteremic Agents; Area Under Curve; Azetidines; Cholesterol; Cholesterol Ester Transfer Proteins; Cricetinae; Diet, High-Fat; Drug Evaluation, Preclinical; Dyslipidemias; Esters; Ezetimibe; High-Density Lipoproteins, Pre-beta; Humans; Intestinal Absorption; Male; Mesocricetus; Oxazolidinones; Sulfhydryl Compounds | 2013 |
CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism.
Topics: Amides; Animals; Anticholesteremic Agents; Cholesterol; Cholesterol Ester Transfer Proteins; Down-Regulation; Dyslipidemias; Esters; Hep G2 Cells; Hepatocytes; Humans; Lipids; Male; Oxazolidinones; Proprotein Convertase 9; Proprotein Convertases; Receptors, LDL; Serine Endopeptidases; Sterol Regulatory Element Binding Protein 2; Sulfhydryl Compounds | 2014 |
Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
Topics: Amides; Animals; Anticholesteremic Agents; Biological Transport; Cholesterol; Cholesterol Ester Transfer Proteins; Cricetinae; Dyslipidemias; Esters; Feces; Macrophages; Male; Oxazolidinones; Sulfhydryl Compounds; Triglycerides | 2014 |
Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.
Topics: Animals; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, VLDL; Down-Regulation; Drug Evaluation, Preclinical; Dyslipidemias; Female; Gene Expression; Gene Regulatory Networks; Hypolipidemic Agents; Lipid Metabolism; Metabolic Networks and Pathways; Mice, Transgenic; Oxazolidinones; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases | 2015 |
Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.
Topics: Animals; Anticholesteremic Agents; Apolipoprotein E3; Aryldialkylphosphatase; Benzodiazepines; Biomarkers; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Diet, High-Fat; Disease Models, Animal; Dyslipidemias; Endothelium, Vascular; Female; Genetic Predisposition to Disease; Humans; Mice, Transgenic; Oxazolidinones; Phenotype; Reactive Oxygen Species; Triglycerides; Up-Regulation; Vasodilation | 2017 |
Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib.
Topics: Animals; Anti-Inflammatory Agents; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Cells, Cultured; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials as Topic; Dyslipidemias; Foam Cells; Humans; Hypolipidemic Agents; Inflammation; Inflammation Mediators; Lipoproteins; Macrophages; Mice; Mice, Knockout; Niacin; Oxazolidinones; Time Factors; Toll-Like Receptor 4; Treatment Outcome | 2010 |
Anacetrapib.
Topics: Atherosclerosis; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Coronary Disease; Dyslipidemias; Humans; Hypercholesterolemia; Oxazolidinones | 2010 |
Trial watch: hope renewed for strategy to raise HDL cholesterol.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials, Phase II as Topic; Dyslipidemias; Humans; Oxazolidinones; Quinolines; Risk Factors | 2011 |
The DEFINE study: a bright future for CETP inhibitors?
Topics: Animals; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Humans; Oxazolidinones; Quinolines | 2011 |
Novel cholesteryl ester transfer protein inhibitors: promising therapy for dyslipidemia?
Topics: Cholesterol Ester Transfer Proteins; Drugs, Investigational; Dyslipidemias; Humans; Hypolipidemic Agents; Molecular Targeted Therapy; Oxazolidinones; Quinolines | 2011 |
Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters.
Topics: Animals; Biological Transport; Cell Line; Cholesterol; Cholesterol Ester Transfer Proteins; Cricetinae; Dyslipidemias; Feces; Lipoproteins, HDL; Macrophages; Male; Mice; Oxazolidinones | 2011 |
Treating high-density lipoprotein cholesterol: a return to inhibition of cholesteryl ester transfer protein?
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Heart Diseases; Humans; Oxazolidinones; Quinolines; Risk Factors | 2008 |